184357-44-6

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI) is used as a pharmaceutical intermediate for the synthesis of various drugs. It plays a crucial role in the development of new pharmaceutical compounds, contributing to the advancement of medical treatments.
Used in Organic Synthesis:
This chemical compound is also used as a reagent in organic synthesis. It aids in the formation of new chemical entities and facilitates various chemical reactions, contributing to the discovery and production of new organic compounds.
Used in Polymer Production:
Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI) is utilized as a stabilizer in the production of polymers. It helps maintain the stability and quality of polymers during their synthesis, ensuring the production of high-quality polymer materials.
Safety Precautions:

InChI:InChI=1/C10H21NO3/c1-9(2,3)14-8(13)11-6-10(4,5)7-12/h12H,6-7H2,1-5H3,(H,11,13)

Upstream product

• 18303-04-3 N-[(tert-butoxy)carbonyl]-4-methylbenzenesulfonamide 
• 91230-06-7 3--2-methylprop-1-ene 
• 529409-31-2 N-(p-toluenesulfonyl)-N-(tert-butoxycarbonyl)-methallylamine 
• 26734-09-8 3-amino-2,2-dimethylpropan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 889125-79-5 methyl 2-(3-tert-butoxycarbonylamino-2,2-dimethylpropoxy)-4-(tert-butyl)-benzoate 
• 889108-00-3 2-(3-tert-butoxycarbonylamino-2,2-dimethylpropoxy)-4-(tert-butyl)-benzoic acid 
• 889120-62-1 2-[2-(3-tert-butoxycarbonylamino-2,2-dimethylpropoxy)-4-(tert-butyl)benzoyl-amino]-N-(5-chloropyridin-2-yl)benzamide 
• 889120-63-2 2-[2-(3-amino-2,2-dimethylpropoxy)-4-(tert-butyl)benzoylamino]-N-(5-chloropyridin-2-yl)benzamide 
• 856244-25-2 (2S)-3-{4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-2-{2-[3-(tert-butoxycarbonylamino)-3-methylpropoxycarbonylamino]ethylsulfonylamino}propionic acid 
• 180181-02-6 3-(tert-Butoxycarbonyl)amino-2,2-dimethylpropanoic Acid 
• 16047-86-2 2,2-dimethyl-3-(methylamino)propan-1-ol 
• 1443216-72-5 C₂₉H₃₉N₅O₆ 

Relevant academic research and scientific papers

Lead evaluation of tetrahydroquinolines as nonsteroidal selective androgen receptor modulators for the treatment of osteoporosis

Tetrahydroquinoline (THQ) was deemed to be a suitable scaffold for our nonsteroidal selective androgen receptor modulator (SARM) concept. We adapted the strategy of switching the antagonist function of cyano-group-containing THQ (CN-THQ) to the agonist function and optimized CN-THQ as an orally available drug candidate with suitable pharmacological and ADME profiles. Based on binding mode analyses and synthetic accessibility, we designed and synthesized a compound that possesses a para-substituted aromatic ring attached through an amide linker. The long-tail THQ derivative 6-acetamido-N-(2-(8-cyano-3a,4,5,9b- tetrahydro-3H-cyclopenta[c]quinolin-4-yl)-2-methylpropyl)nicotinamide (1 d), which bears a para-acetamide-substituted aromatic group, showed an appropriate in vitro biological profile, as expected. We considered that the large conformational change at Trp741 of the androgen receptor (AR) and the hydrogen bond between 1 d and helix 12 of the AR could maintain the structure of the AR in its agonist form; indeed, 1 d displays strong AR agonistic activity. Furthermore, 1 d showed an appropriate in vivo profile for use as an orally available SARM, displaying clear tissue selectivity, with a separation between its desirable osteoanabolic effect on femoral bone mineral density and its undesirable virilizing effects on the uterus and clitoral gland in a female osteoporosis model. Long-tail THQ as a SARM: We describe the lead evaluation process of tetrahydroquinolines (THQs) as nonsteroidal selective androgen receptor modulators (SARMs). The strategy of switching from AR antagonist to AR agonist was successfully applied to CN-THQ, and we identified a long-tail THQ as a novel SARM. This new THQ showed a certain degree of tissue selectivity, with a separation between its desirable osteoanabolic effect and its undesirable virilizing effects in a female osteoporosis model. Copyright

NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS

The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding compositions, and methods and/or uses in therapy, for example in the treatment of parasitic infections such as malaria, in particular infection by

3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS

The present invention relates to bisaryl lactam compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the compounds of this invention include a compound of Formula (I):

Novel benzoxazolone compound

PROBLEM TO BE SOLVED: To provide a therapeutic agent for diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small diameter fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria or multiple sclerosis. SOLUTION: There is provided a benzoxazolone compound represented by the formula (1) or a pharmaceutically acceptable salt. (1), where R1 and R2 are each independently H or C1-6 alkyl, where the alkyl may be substituted by hydroxy, C1-4 alkylsulfonyl, aminocarbonyl or 4 to 7-membered heterocycloalkyl, or the like, L is C1-6 alkylene, R3 is C1-6 alkyl, C3-7 cycloalkyl, where the cycloalkyl may be substituted by halogen or hydroxy or the like, C6-10 aryl, where the aryl may be substituted by halogen, C1-4 alkyl or C1-4 haloalkyl or the like, R4 is H, halogen or C1-4 alkyl. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

LSD1 INHIBITORS AND USES THEREOF

Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSDl.

HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR

The present invention provides a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. For example, the present invention provides a heterocyclic derivative of the general formula [1] or its tautomer, or a pharmaceutically acceptable salt thereof: wherein R 1 and R 2 are same or diferent aromatic ring, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevension of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease.

TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS

There is provided compounds of formula (I), wherein R1, R2, X, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).

HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

HETEROCYCLIC COMPOUND

The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound re